Indian pharma market grows 7.2% in May, led by chronic therapies

The Indian Pharmaceutical Market (IPM) grew by 7.2% in May 2025, with most major therapy areas recording positive growth, according to market research firm Pharmarack. Chronic therapies such as cardiac and anti-infectives, which jointly account for about 25% of the market, posted value growth of 11.7% and 7.6%, respectively. Smaller therapy areas like urology and antineoplastics, contributing 2% each to overall monthly sales, saw strong double-digit growth at 12.3% and 11.7%. Price increases and new product launches primarily drove the overall growth, though unit growth remained low at 0.4%.
Chronic therapies outperformed the broader market, with antidiabetics growing 6.1% in volume, largely due to empagliflozin going off-patent and the launch of new combinations. The market's moving annual turnover (MAT) between June 2024 and May 2025 rose 8.1%, reaching over Rs. 2,29,000 crore (US$ 26.72 billion), with domestic volume growth at 1.1%. Key therapy segments like cardiac, gastrointestinal, and anti-infectives, which form around 38% of IPM, saw volume growth of 10.4%, 9.5%, and 6.5%, respectively. While the top 20 brands posted moderate growth, companies such as Sun Pharma and Dr Reddy’s each recorded 11.2% growth, followed by Torrent Pharma and Ipca Laboratories at 10.8% and Alkem Laboratories at 10.3%. Top-selling medicines included GlaxoSmithKline’s Augmentin Rs. 819 crore (US$ 95.57 million) and USV’s Glycomet GP Rs. 810 crore (US$ 94.52 million) at the MAT level.

Disclaimer: This information has been collected through secondary research and IBEF is not responsible for any errors in the same.